📣 VC round data is live. Check it out!

Promimic Valuation Multiples

Discover revenue and EBITDA valuation multiples for Promimic and similar public comparables like Modular Medical, Polyrizon, European Medical Solutions, EVION Group and more.

Promimic Overview

About Promimic

Promimic AB is a biomaterial company producing a nano-thin surface for all implant materials for faster osseointegration.


Founded

2004

HQ

Sweden

Employees

N/A

Financials (FY)

Revenue: $5M
EBITDA: ($211K)

EV

$24M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Promimic Financials

Promimic reported last fiscal year revenue of $5M and negative EBITDA of ($211K).

In the same fiscal year, Promimic generated $5M in gross profit, ($211K) in EBITDA losses, and had net loss of ($941K).


Promimic P&L

In the most recent fiscal year, Promimic reported revenue of $5M and EBITDA of ($211K).

Promimic is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (4%), and net margin of (20%).

See analyst estimates for Promimic
Last FY202320242025202620272028
Revenue$5M$4M$5M$5M
Gross Profit$5M$4M$5M$5M
Gross Margin100%104%109%100%
EBITDA($211K)($388K)($397K)($211K)
EBITDA Margin(4%)(10%)(8%)(4%)
EBIT Margin(21%)(27%)(20%)(21%)
Net Profit($941K)($991K)($1M)($941K)
Net Margin(20%)(25%)(29%)(20%)

Financial data powered by Morningstar, Inc.

Promimic Stock Performance

Promimic has current market cap of $26M, and enterprise value of $24M.

Market Cap Evolution


Promimic's stock price is $1.38.

Promimic share price decreased by 12.5% in the last 30 days, and by 29.1% in the last year.

Promimic has an EPS (earnings per share) of $-0.05.

See more trading valuation data for Promimic
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$24M$26M-11.8%-12.5%-8.5%-29.1%$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Promimic Valuation Multiples

Promimic trades at 5.0x EV/Revenue multiple, and (112.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Promimic

Promimic Financial Valuation Multiples

As of June 3, 2026, Promimic has market cap of $26M and EV of $24M.

Promimic has a P/E ratio of (27.6x).

Last FY202320242025202620272028
EV/Revenue5.0x6.0x5.0x5.0x
EV/EBITDA(112.5x)(61.3x)(59.8x)(112.5x)
EV/EBIT(23.8x)(22.0x)(25.2x)(23.8x)
EV/Gross Profit5.0x5.7x4.6x5.0x
P/E(27.6x)(26.2x)(19.3x)(27.6x)
EV/FCF(17.0x)(16.9x)(10.9x)(17.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Promimic Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Promimic Margins & Growth Rates

In the most recent fiscal year, Promimic reported gross margin of 100%, EBITDA margin of (4%), and net margin of (20%).

See estimated margins and future growth rates for Promimic

Promimic Margins

Last FY20242025202720282029
Gross Margin100%109%100%
EBITDA Margin(4%)(8%)(4%)
EBIT Margin(21%)(20%)(21%)
Net Margin(20%)(29%)(20%)
FCF Margin(29%)(46%)(29%)

Promimic Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth19%1%
Gross Profit Growth25%(8%)
EBITDA Growth2%(47%)
EBIT Growth(13%)6%
Net Profit Growth36%(30%)
FCF Growth55%(36%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Promimic Operational KPIs

Access forward-looking KPIs for Promimic
Last FY202320242025202620272028
Opex to Revenue120%131%129%120%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Promimic Competitors

Promimic competitors include Modular Medical, Polyrizon, European Medical Solutions, EVION Group, NanoRepro, IMD International Medical, CS Diagnostics, Egide, Medclair and Nova Eye Medical.

Most Promimic public comparables operate across Advanced Materials, Medical Devices, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Modular Medical--(1.3x)-
Polyrizon--(4.9x)-
European Medical Solutions0.7x-7.3x-
EVION Group----
NanoRepro3.5x1.0x(4.7x)(14.9x)
IMD International Medical0.4x-5.8x-
CS Diagnostics----
Egide0.8x-(104.0x)-

This data is available for Pro users. Sign up to see all Promimic competitors and their valuation data.

Start Free Trial

Promimic VC Funding History

Before going public, Promimic raised $7M in total equity funding, across 3 rounds.


Promimic Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-19SeedChalmers Ventures AB$2M--
Apr-18SeedChalmers Ventures AB$1M--
Sep-16SeedAlmi Invest; Chalmers Ventures AB; Karolinska Development$3M-Promimic is a Swedish biomaterials company founded in 2004 that develops HAnano Surface, a nanometer-thin surface treatment designed to improve the anchorage and healing of orthopedic and dental implants into bone tissue. The technology had been applied to over 700,000 implants in clinical use globally as of the round date. On September 13, 2016, Promimic raised SEK 23.8 million (USD 3.2 million) in Series A funding to establish commercial operations in the United States, the world's largest market for medical implants. Chalmers Ventures led the round as a new investor, with existing investors Karolinska Development and Almi Invest participating. The capital was intended to finance the expansion of the company's international business efforts. The funding came after significant progress during the preceding 12 months, including a partnership launch with Sistema de Implante Nacional (S.I.N), a leading Brazilian dental implant provider, which had introduced the first product using Promimic's HAnano Surface technology in Brazil in January 2016. The companies were engaged in an extensive pre-clinical and clinical development program for enhanced dental implants at the time of the funding announcement.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Promimic

When was Promimic founded?Promimic was founded in 2004.
Where is Promimic headquartered?Promimic is headquartered in Sweden.
Is Promimic publicly listed?Yes, Promimic is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Promimic?Promimic trades under PRO ticker.
When did Promimic go public?Promimic went public in 2022.
Who are competitors of Promimic?Promimic main competitors include Modular Medical, Polyrizon, European Medical Solutions, EVION Group, NanoRepro, IMD International Medical, CS Diagnostics, Egide, Medclair, Nova Eye Medical.
What is the current market cap of Promimic?Promimic's current market cap is $26M.
What is the current revenue of Promimic?Promimic's last fiscal year revenue is $5M.
What is the current EV/Revenue multiple of Promimic?Current revenue multiple of Promimic is 5.0x.
Is Promimic profitable?No, Promimic is not profitable.
How many companies Promimic has acquired to date?Promimic hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Promimic has invested to date?Promimic hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Promimic

Lists including Promimic

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial